AKT1 and hepatocellular carcinoma: In addition, it has been reported that lncRNA-PDPK2P promotes HCC progression by modulating the PDK1/AKT/Caspase three signaling pathway, indicating this lncRNA might serve as a molecular target for HCC therapy.